All In MedTech

FDA Clearance Tracker · P130009-S105

Edwards SAPIEN XT Transcatheter Heart Valve

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 10, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P130009-S105
Device name
Edwards SAPIEN XT Transcatheter Heart Valve
Applicant location
Irvine, CA
Received
Nov 18, 2019
Decided
Apr 10, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P130009

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site located at Edwards Lifesciences (Singapore) Pte. Ltd, 35 Changi North Crescent, Singapore 499641 SG, to receive and process bovine pericardial tissue sacs into treated tissue heart valve leaflets.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.